The studies presented here clearly suggest that the ability of penetrating the blood–brain barrier makes nanoparticles excellent candidates to be applied in AD treatment, especially by inhibiting the fibrillation process and toxic effects of amyloid beta peptide. Here, APP is linked to Alzheimer disease.